Pharmafile Logo

Glioblastoma mutliforme

Gilead Sciences

Sovaldi pushes Gilead to the top of US pharma list

Blockbuster hep c pill sees the firm go from fourteenth to first in just one year

Bristol-Myers Squibb (BMS) building

BMS buys into gene therapy with $1bn uniQure alliance

US firm on a deal spree in 2015 as it racks up yet another collaboration

- PMLiVE

PD-1 cancer market overrated, says new report

The immuno-oncology market for new oncology drugs may be worth half of current expectations

- PMLiVE

Merck’s Keytruda beats BMS’ Yervoy in melanoma face-off

Both firms competing for a leading share in the highly competitive skin cancer drug market

- PMLiVE

Novo Nordisk sheds autoimmune portfolio to BMS

Continues the trend of pharma buying up unwanted assets from rival firms

- PMLiVE

AstraZeneca bullish on diabetes franchise fortunes

Other big pharma firms face a difficult 2015, but AZ is confident it won't

Bristol-Myers Squibb (BMS) building

Opdivo gains new US lung cancer licence

Adds to Bristol-Myers Squibb’s therapeutic vaccine’s melanoma indication

- PMLiVE

Personalised cancer medicines showcased in BBC investigation

Panorama looked at cutting-edge science and the new generation of oncology drugs

Bristol Myers Squibb logo

BMS and Lilly to jointly research Opdivo combination

PD-1 inhibitor will be tested with Lilly's galunisertib

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo set for early access in UK

First anti-PD1 to be given fast-track status in the country

Bristol-Myers Squibb (BMS) building

BMS cancer drug Opdivo gains US melanoma licence

Therapeutic vaccine can now be used against the deadliest form of skin cancer

Bristol-Myers Squibb (BMS) building

Opdivo to be tested as ‘double immunotherapy’ for tumours

BMS and Ono to test anti-PD-1 in combination with Kyowa Hakko's mogamulizumab

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links